| Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) B Nagar, WG Bornmann, P Pellicena, T Schindler, DR Veach, WT Miller, ... Cancer research 62 (15), 4236-4243, 2002 | 1307 | 2002 |
| Structural basis for the autoinhibition of c-Abl tyrosine kinase B Nagar, O Hantschel, MA Young, K Scheffzek, D Veach, W Bornmann, ... Cell 112 (6), 859-871, 2003 | 1041 | 2003 |
| Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas SP Gao, KG Mark, K Leslie, W Pao, N Motoi, WL Gerald, WD Travis, ... The Journal of clinical investigation 117 (12), 3846-3856, 2007 | 768 | 2007 |
| L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition CR Antonescu, KJ Busam, TD Francone, GC Wong, T Guo, NP Agaram, ... International journal of cancer 121 (2), 257-264, 2007 | 286 | 2007 |
| Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases PM Reeves, B Bommarius, S Lebeis, S McNulty, J Christensen, A Swimm, ... Nature medicine 11 (7), 731-739, 2005 | 263 | 2005 |
| Gleevec inhibits β-amyloid production but not Notch cleavage WJ Netzer, F Dou, D Cai, D Veach, S Jean, Y Li, WG Bornmann, ... Proceedings of the National Academy of Sciences 100 (21), 12444-12449, 2003 | 253 | 2003 |
| Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases D Wisniewski, CL Lambek, C Liu, A Strife, DR Veach, B Nagar, MA Young, ... Cancer research 62 (15), 4244-4255, 2002 | 214 | 2002 |
| Two distinct phosphorylation pathways have additive effects on Abl family kinase activation KQ Tanis, D Veach, HS Duewel, WG Bornmann, AJ Koleske Molecular and cellular biology, 2003 | 200 | 2003 |
| Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor T Guo, NP Agaram, GC Wong, G Hom, D D'Adamo, RG Maki, ... Clinical Cancer Research 13 (16), 4874-4881, 2007 | 172 | 2007 |
| Loss of p53 impedes the antileukemic response to BCR-ABL inhibition HG Wendel, E de Stanchina, E Cepero, S Ray, M Emig, JS Fridman, ... Proceedings of the National Academy of Sciences 103 (19), 7444-7449, 2006 | 168 | 2006 |
| A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor N Von Bubnoff, DR Veach, H Van Der Kuip, WE Aulitzky, J Sänger, ... Blood 105 (4), 1652-1659, 2005 | 141 | 2005 |
| Enteropathogenic Escherichia coli Use Redundant Tyrosine Kinases to Form Actin Pedestals A Swimm, B Bommarius, Y Li, D Cheng, P Reeves, M Sherman, D Veach, ... Molecular biology of the cell 15 (8), 3520-3529, 2004 | 132 | 2004 |
| Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance M Azam, V Nardi, WC Shakespeare, CA Metcalf III, RS Bohacek, Y Wang, ... Proceedings of the National Academy of Sciences 103 (24), 9244-9249, 2006 | 126 | 2006 |
| Mechanisms of Sunitinib Resistance in Gastrointestinal Stromal Tumors Harboring KITAY502-3ins Mutation: An In vitro Mutagenesis Screen for Drug Resistance T Guo, M Hajdu, NP Agaram, H Shinoda, D Veach, BD Clarkson, RG Maki, ... Clinical Cancer Research 15 (22), 6862-6870, 2009 | 109 | 2009 |
| Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors N Von Bubnoff, DR Veach, WT Miller, W Li, J Sänger, C Peschel, ... Cancer research 63 (19), 6395-6404, 2003 | 105 | 2003 |
| Positron emission tomography/computed tomography–based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration … JJ Fox, SC Gavane, E Blanc-Autran, S Nehmeh, M Gönen, B Beattie, ... JAMA oncology 4 (2), 217-224, 2018 | 99 | 2018 |
| Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation X Deng, ER Hofmann, A Villanueva, O Hobert, P Capodieci, DR Veach, ... Nature genetics 36 (8), 906-912, 2004 | 98 | 2004 |
| PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia NC Wolff, DR Veach, WP Tong, WG Bornmann, B Clarkson, RL Ilaria Jr Blood 105 (10), 3995-4003, 2005 | 91 | 2005 |
| Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate. AJ Tipping, S Baluch, DJ Barnes, DR Veach, BM Clarkson, WG Bornmann, ... Leukemia (08876924) 18 (8), 2004 | 66 | 2004 |
| Quantification of change in phosphorylation of BCR‐ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells X Liang, M Hajivandi, D Veach, D Wisniewski, B Clarkson, MD Resh, ... Proteomics 6 (16), 4554-4564, 2006 | 62 | 2006 |
